SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Aurobindo Pharma reports consolidated Q3 net loss of Rs 28.54 crore

14 Feb 2012 Evaluate

Drug firm, Aurobindo Pharma has reported consolidated net loss of Rs 28.54 crore for the quarter ended December 31, 2011, against net profit of Rs 188.63 crore for the corresponding period last fiscal. The group’s consolidated net sales rose by 7.74% to Rs 1,284.51 crore during the quarter under review from Rs 1,192.20 crore in the year-ago period.

On a standalone basis, the company posted a net profit of Rs 12.93 crore for the third quarter ended December 31, 2011, as against Rs 183.85 crore in the same period last fiscal. Net sales rose by 3.88% to Rs 1,201.50 crore during the quarter under review from Rs 1,156.61 crore in the year-ago period.

Aurobindo Pharma Share Price

1488.50 9.95 (0.67%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×